Poolbeg Pharma plc – ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost
Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres
25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company.
